State Activities: Impact on the U.S. Pharmaceutical Industry

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• State Legislatures Taking Action Against Serious Drug Concerns
  • 2007 State Legislative Bills
• Northern States Push for Drug Reimportation
  • Political Maneuverings Create “Poison Pills”
  • Vested Interests: Politicians, Lobbyists, and Patients
  • Effects of Looming Presidential and Congressional Elections
• Battle Lines Drawn Over Access to Prescriber-Identifi able Prescription Data
  • New Hampshire' s Prescription Information Law
  • AMA National Prescribing Data Restriction Program
• Electronic Health Records-Interoperability, Transparency, and Accountability for All
  • National Health Information Network
  • State Alliance for e-Health
• State Attorneys General Not Afraid to Litigate
  • State Antitrust Enforcement
  • Average Wholesale Price Manipulations and State Litigation
• Educating Physicians: Evidence-Based Medicine and Counter-Detailing
  • Pennsylvania' s PACE Program
  • The Drug Effectiveness Review Project
  • The Prescription Project
• States Are Funding Research That Benefi ts the Pharma Industry
  • Economic Development Through State Life Sciences Initiatives
  • Stem Cell Funding Initiatives
• Access to Affordable Medicines
  • State Children' s Health Insurance Program
  • State Pharmaceutical Assistance Programs
  • States Push for Generics
  • Industry' s Helping Hand
• Mandatory Human Papillomavirus Vaccine Legislation
  • Just Another Cancer Drug or First-Ever Vaccine?
  • A New Challenge for Pharmaceutical Companies
• State-Sponsored Universal Health Care
  • States Taking the Lead on Universal Health Care
  • Businesses Attempt Health Care Reform
• Capturing the Future

Figures

• 1. Factors Contributing to Total Prescription Drug Spending Growth, 1988-2016
• 2. United States Expenditures on Prescription Drugs, 2000, 2005, and 2016
• 3. Prescription Drug State Legislation, 2007
• 4. Drug Reimportation Timeline: Politics, Patients' Rights, and Pharmaceutical Industry Lobbying
• 5. Timeline of Select Stem Cell Research Activities in Different States, 2000-2007
• 6. SCHIP Funds: Allocation Versus Spending, 1998-2007
• 7. State Pharmaceutical Assistance Programs, 2006
• 8. Health Insurance Premiums, Percentage Increase, 1996-2006
• 9. Status of State Initiatives for Health Care Reform

Sidebars

• New Hampshire House Bill 1346-An Act requiring certain persons to keep the contents of prescriptions confi dential (excerpt)
• Human Papillomavirus, Cancer, and Sexually Transmitted Disease

Tables

• 1. State e-Health Initiatives-Channels for Creating Health Information Technology Networks, 2007
• 2. States Take Legal Action Against Pharmaceutical Companies
• 3. Relative Advantages of Life Sciences Clusters in Three States, 2002
• Appendix-State Drug Assistance Programs, 2007